-
Innovation Ranking
NewInnovation Ranking – Cipla Ltd
Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new...
-
Product Insights
Cipla Tuljapur Solar PV Park
Cipla Tuljapur Solar PV Park is a solar PV project located in Maharashtra, India. The project is owned by Ampin Energy Transition Pvt Ltd and was developed by Amp Energy Green Pvt Ltd. The project came online in 2020. Empower your strategies with our Cipla Tuljapur Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
Cipla Tuljapur Solar PV Park 2
Cipla Tuljapur Solar PV Park 2 is a solar PV project located in Maharashtra, India. The project is owned and developed by Ampin Energy Transition Pvt Ltd. The project came online in 2022. Empower your strategies with our Cipla Tuljapur Solar PV Park 2 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Company Insights
Innovation and Patenting activity of Cipla Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cipla Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Abacavir Sulfate + Lamivudine + Lopinavir + Ritonavir) in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Abacavir Sulfate + Lamivudine + Lopinavir + Ritonavir) in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Abacavir...
-
Product Insights
Cryptococcal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cryptococcal Meningitis - Drugs In Development, 2023’, provides an overview of the Cryptococcal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryptococcal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fungal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Fungal Meningitis - Drugs In Development, 2023’, provides an overview of the Fungal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fungal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Meningitis - Drugs In Development, 2023’, provides an overview of the Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...